Anna F. Farago, MD, PhD
Advertisement
Articles by Anna F. Farago, MD, PhD
Cancer Network spoke with Anna F. Farago, MD, of Massachusetts General Hospital, about the effect of trilaciclib on myelosuppression in patients with previously treated extensive-stage small-cell lung cancer receiving topotecan.
Advertisement
Latest Updated Articles
Dr. Farago on Trilaciclib for Myelosuppression in Previously Treated Extensive-Stage SCLCPublished: June 11th 2019 | Updated:
Dr. Anna F. Farago New Cytotoxic Strategies for Relapsed Small-Cell Lung CancerPublished: June 12th 2019 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
How to Address Racial and Social Disparities in Pancreatic Cancer Care?
2
Handling the Burden of Financial Toxicity While Undergoing Cancer Therapy
3
As Late-Career Oncologists Retire, Who Will Fill the Geographic Gaps?
4
PEG Hydrogel Reduces Rectal Radiation During Cervical Cancer Therapy
5
